Success Metrics

Clinical Success Rate
94.6%

Based on 261 completed trials

Completion Rate
95%(261/276)
Active Trials
6(2%)
Results Posted
51%(134 trials)
Terminated
15(5%)

Phase Distribution

Ph early_phase_1
1
0%
Ph phase_2
17
6%
Ph phase_4
109
37%
Ph phase_3
118
41%
Ph phase_1
38
13%
Ph not_applicable
7
2%

Phase Distribution

39

Early Stage

17

Mid Stage

227

Late Stage

Phase Distribution290 total trials
Early Phase 1First-in-human
1(0.3%)
Phase 1Safety & dosage
38(13.1%)
Phase 2Efficacy & side effects
17(5.9%)
Phase 3Large-scale testing
118(40.7%)
Phase 4Post-market surveillance
109(37.6%)
N/ANon-phased studies
7(2.4%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

94.2%

261 of 277 finished

Non-Completion Rate

5.8%

16 ended early

Currently Active

6

trials recruiting

Total Trials

291

all time

Status Distribution
Active(6)
Completed(261)
Terminated(16)
Other(8)

Detailed Status

Completed261
Terminated15
unknown8
Recruiting4
Active, not recruiting2
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
291
Active
6
Success Rate
94.6%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (0.3%)
Phase 138 (13.1%)
Phase 217 (5.9%)
Phase 3118 (40.7%)
Phase 4109 (37.6%)
N/A7 (2.4%)

Trials by Status

withdrawn10%
recruiting41%
unknown83%
active_not_recruiting21%
completed26190%
terminated155%

Recent Activity

6 active trials
Showing 5 of 291
completedphase_3

A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

NCT05803421
completedphase_3

A Research Study to See How Well New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Levels in People With Type 2 Diabetes (T2D), Compared to Daily Insulin Glargine (COMBINE 4)

NCT06269107
completedphase_3

A Research Study to See How Switching From a Daily Basal Insulin to a New Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine in Adults With Type 2 Diabetes

NCT06340854
completedphase_2

Effect of Topical Insulin on Healing Rate of Pemphigus Lesions

NCT07461103
completedphase_3

A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes

NCT01794143
View all 291 trials

Clinical Trials (291)

Showing 20 of 291 trialsScroll for more
NCT05803421Phase 3

A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Completed
NCT06269107Phase 3

A Research Study to See How Well New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Levels in People With Type 2 Diabetes (T2D), Compared to Daily Insulin Glargine (COMBINE 4)

Completed
NCT06340854Phase 3

A Research Study to See How Switching From a Daily Basal Insulin to a New Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine in Adults With Type 2 Diabetes

Completed
NCT07461103Phase 2

Effect of Topical Insulin on Healing Rate of Pemphigus Lesions

Completed
NCT01794143Phase 3

A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes

Completed
NCT06881264Phase 3

A Study Comparing HR17031 With Insulin Glargine in Patients With Type 2 Diabetes

Completed
NCT06871761Phase 3

A Trial Comparing HR17031 With Insulin Glargine in Patients With Type 2 Diabetes

Completed
NCT07076199Phase 3

A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes

Recruiting
NCT07282054Phase 3

Efficacy and Safety of THDB0206 Compared to Insulin Lispro Injection in Participants With Type 1 Diabetes

Completed
NCT04460885Phase 3

A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Glargine, in People With Type 2 Diabetes Who Have Not Used Insulin Before

Completed
NCT04880850Phase 3

A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Glargine, Both in Combination With Mealtime Insulin, in People With Type 2 Diabetes Who Use Daily Insulin and Mealtime Insulin (ONWARDS 4)

Completed
NCT05013229Phase 3

A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Insulin Glargine Taken Daily With Insulin Aspart (COMBINE 3)

Completed
NCT06688123Phase 2

Efficacy and Safety of SHR-3167 and Insulin Glargine in Type 2 Diabetes Subjects

Active Not Recruiting
NCT06370715Phase 4

A Study of LY900014 in Adult Participants With Type 2 Diabetes Mellitus in India

Completed
NCT05614089Phase 4

Human Versus Analogue Insulin for Youth With Type 1 Diabetes in Low-Resource Settings

Completed
NCT05662332Phase 3

A Study of Insulin Efsitora Alfa (LY3209590) Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time (QWINT-1)

Completed
NCT05098470Phase 3

Effects of Modulators of Gluconeogenesis, Glycogenolysis and Glucokinase Activity

Active Not Recruiting
NCT05702073Phase 3

To Compare the Efficacy and Safety of INS068 and Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin.

Completed
NCT05699408Phase 3

To Compare the Efficacy and Safety of INS068 and Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Not Adequately Controlled With Oral Antidiabetic Drugs

Completed
NCT03087032Phase 4

Liraglutide-bolus vs Glargine-bolus Therapy in Overweight/Obese Type 2 Diabetes Patients (LiraGooD)

Recruiting

Drug Details

Intervention Type
DRUG
Total Trials
291